Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Intelligent Bio Solutions Inc. reported revenue of $3M, down 1.9% year over year. Operating margin was -348.7% and net margin -346.2%, on a free-cash-flow margin of -324.6% with capital expenditure at 7.6% of revenue. Every figure is computed directly from INBS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3M | -348.7% | -346.2% |
| FY2024 | $3M | -330.5% | -326.4% |
| FY2023 | $1M | -1002.1% | -845.9% |
| FY2022 | $0M | -1907.1% | -1900.1% |
| FY2021 | $2M | -281.4% | -355.3% |
How does INBS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.